Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation.
Autologous stem cell transplantation
Lenalidomide
Multiple myeloma
Secondary primary malignancies
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
06
08
2018
accepted:
19
09
2018
revised:
18
09
2018
pubmed:
27
9
2018
medline:
7
2
2019
entrez:
26
9
2018
Statut:
ppublish
Résumé
Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation. However, because of their increased life expectancy, an increased risk of secondary primary malignancies (SPMs) has been observed in MM patients, particularly after lenalidomide maintenance in both transplant-eligible (TE) and transplant-ineligible (TI) patients. To evaluate the incidence and risk factors of developing SPMs, we identified 17 TE-MM and 12 TI-MM patients with SPMs among 211 TE-MM and 280 TI-MM patients, including seven TE-MM and four TI-MM patients with hematological malignancies and ten TE-MM and eight TI-MM patients with non-hematological cancers, respectively. The median follow-up time from diagnosis was > 4 years. Multivariate analysis identified a history of high-dose cyclophosphamide use for peripheral blood stem cell harvest in TE-MM patients and > 65 years of age at diagnosis, or a history of adriamycin, lenalidomide, or thalidomide use in TI-MM patients as independent risk factors for SPMs (P < 0.001). Patients with a history of lenalidomide use had a lower risk of death among both TE-MM (P = 0.0326) and TI-MM (P < 0.001) patients. The survival benefit of receiving lenalidomide outweighed the increased risk of SPMs in both TE-and TI-MM patients.
Identifiants
pubmed: 30251131
doi: 10.1007/s12185-018-2538-8
pii: 10.1007/s12185-018-2538-8
doi:
Substances chimiques
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
98-106Références
Lancet Oncol. 2003 May;4(5):293-304
pubmed: 12732167
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Bone Marrow Transplant. 2007 Jan;39(2):59-70
pubmed: 17143301
Chem Biol Interact. 2010 Mar 19;184(1-2):50-7
pubmed: 19958752
J Clin Oncol. 2010 Feb 10;28(5):830-4
pubmed: 20038719
Mucosal Immunol. 2011 Nov;4(6):603-11
pubmed: 21975936
Br J Haematol. 2012 Mar;156(5):683-6
pubmed: 22050384
Haematologica. 2012 Jun;97(6):805-17
pubmed: 22180424
N Engl J Med. 2012 May 10;366(19):1759-69
pubmed: 22571200
N Engl J Med. 2012 May 10;366(19):1770-81
pubmed: 22571201
N Engl J Med. 2012 May 10;366(19):1782-91
pubmed: 22571202
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Intern Med. 2013;52(1):63-70
pubmed: 23291675
Int J Hematol. 2013 Sep;98(3):337-45
pubmed: 23877150
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
Lancet Oncol. 2014 Mar;15(3):333-42
pubmed: 24525202
Blood. 2014 Jul 24;124(4):536-45
pubmed: 24914135
Int J Hematol. 2014 Aug;100(2):159-64
pubmed: 24928523
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
JAMA Dermatol. 2015 Jul;151(7):775-82
pubmed: 25902409
Haematologica. 2015 Oct;100(10):1340-9
pubmed: 26160877
Leuk Lymphoma. 2017 Mar;58(3):560-568
pubmed: 27424609
Cancer Med. 2017 Jan;6(1):3-11
pubmed: 27860411
Ann Oncol. 2017 Feb 1;28(2):228-245
pubmed: 27864218
Blood Cancer J. 2016 Dec 9;6(12):e506
pubmed: 27935580
Int J Hematol. 2017 Apr;105(4):445-452
pubmed: 28000099
Int J Hematol. 2017 Oct;106(4):562-572
pubmed: 28527129
Int J Hematol. 2018 Apr;107(4):460-467
pubmed: 29260507
Biol Blood Marrow Transplant. 2018 May;24(5):930-936
pubmed: 29339268
Int J Hematol. 2018 May;107(5):559-567
pubmed: 29388164
Br J Haematol. 1998 Sep;102(5):1115-23
pubmed: 9753033